Holly Hagan
Holly Hagan, PhD, MPH
CDUHR - Director
CDUHR - Associate Director, Infectious Disease Epidemiology and Social-behavioral Theory Core
NYU School of Global Public Health – Professor
PhD, Epidemiology, University of Washington
MPH, Epidemiology, University of Massachusetts, Amherst
BA, Russian Studies, The Evergreen State College
Research Interests
Epidemiology, Natural history, Prevention and treatment of HCV and HIV in PWID and MSM, Research methods and exploration of study bias
Holly Hagan is a Professor in the Departments of Social Behavioral Sciences and Epidemiology at the NYU School of Global Public Health. Trained as an infectious disease epidemiologist, Dr. Hagan’s work has sought to understand the causes and consequences of substance use disorders.  Her research has examined blood-borne and sexually-transmitted infections among people who use drugs. She is an internationally-recognized expert in the etiology, epidemiology, natural history, prevention and treatment of hepatitis C virus infection among PWUD, and in 2014 her work was recognized by the US Department of Health and Human Services with the President’s Award for Leadership in the Control of Viral Hepatitis in the United States. Dr. Hagan served on the Institute of Medicine Committee on the Prevention and Control of Viral Hepatitis in the United States, and she has been an advisor to the US Department of Health and Human Services, the CDC, and the Canadian Institutes of Health on national programs to detect, diagnose and treat HCV infections. She was appointed to the National Academy of Medicine Committee on the Examination of the Integration of Opioid and Infectious Disease Prevention Efforts in Select Programs. In 2017, she was selected by NIDA to chair the Executive Steering Committee for the Rural Opioid Initiative funded by NIH, CDC, SAMHSA and the Appalachian Regional Commission.
Principal Investigator, Nurse-Community Health Worker-Family Partnership Model to Increase COVID-19 Testing in Urban Underserved and Vulnerable Communities. Active
Principal Investigator, Addressing Hepatitis C and Hepatocellular Carcinoma: The Current and Future Epidemics. Completed
Principal Investigator, Collaborative Injection Drug Users Study III: Drug User Intervention Trial (CIDUS/DUIT). Completed
Principal Investigator, Etiology and Prevention of HCV in IDUs (SPIN Project). Completed
Principal Investigator, National HIV Behavioral Surveillance – New York City. Completed
Principal Investigator, National HIV Behavioral Surveillance Among High Risk Heterosexuals: New York City. Completed
Principal Investigator, National HIV Behavioral Surveillance Among Injection Drug Users: New York City. Completed
Principal Investigator, Overdose Prevention in New York. Completed
Principal Investigator, Reducing HIV Transmission by Promoting Sexual Health Among Drug Users. Completed
Principal Investigator, Study to Reduce Intravenous Exposures (STRIVE). Completed
Principal Investigator, Synthesis: HCV Epidemiology and Prevention in Drug Users. Completed
Principal Investigator, Transition to Injection Drug Use in New York State in the Era of Prescription Opioid Misuse. Completed


Guilamo-Ramos V, Thimm-Kaiser M, Benzekri A, Hidalgo A, Lanier Y, Tlou S, de Lourdes Rosas Lopez M, Soletti AB, Hagan H (2021).
Nurses at the frontline of public health emergency preparedness and response: Lessons learned from the HIV/AIDS pandemic and emerging infectious disease outbreaks
Lancet Infectious Diseases, 21 (10), e326-e333. doi: 10.1016/S1473-3099(20)30983-X. PMCID: PMC7972309.

Jenkins RA, Hagan H (2020).
What is a rural opioid risk and policy environment?
International Journal of Drug Policy, 85, 102606. doi: 10.1016/j.drugpo.2019.11.014. PMCID: PMC7293810.

Guilamo-Ramos V, Benzekri A, Thimm-Kaiser M, Abram M, Hagan H (2020).
Participation of the nursing workforce to address COVID-19 among people who use alcohol, tobacco, and drugs
International Journal of Drug Policy, 83, 102831. doi: 10.1016/j.drugpo.2020.102831.

Stevens ER, Nucifora KA, Hagan H, Jordan AE, Uyei J, Khan B, Dombrowski K, Des Jarlais D, Braithwaite RS (2020).
Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population
Clinical Infectious Diseases, 70 (12), 2652-2662. doi: 10.1093/cid/ciz726. PMCID: PMC7286369.

Chikovani I, Ompad DC, Uchaneishvili M, Sulaberidze L, Sikharulidze K, Hagan H, VanDevanter NL (2019).
On the way to hepatitis C elimination in the Republic of Georgia – Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study
PLoS One, 14 (4), e0216123. doi: 10.1371/journal.pone.0216123. PMCID: PMC6488087.


Hagan H, Jordan AE, Neurer J, Cleland CM (2015).
Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men
AIDS, 29 (17), 2335-2345. doi: 10.1097/QAD.0000000000000834. PMCID: PMC4640945.

Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C (2008).
Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: The influence of time and place
American Journal of Epidemiology, 168 (10), 1099-1109. doi: 10.1093/aje/kwn237. PMCID: PMC2727245.

Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER (2001).
Sharing of drug preparation equipment as a risk factor for hepatitis C
American Journal of Public Health, 91 (1), 42-46. doi: 10.2105/AJPH.91.1.42. PMCID: PMC1446500.

Dr. Hagan's MyBibliography Profile
Selected Press
The White House observed World Hepatitis Day 2014. Holly Hagan was one of 12 leaders recognized for domestic and global work in the prevention and treatment of viral hepatitis.